Catalyst Event
Johnson & Johnson (JNJ) · Other
From Akros U.S. Large Cap 500 Index (AUL500)
5/28/2026, 12:00:00 AM
The FDA approved a label expansion for TREMFYA® (guselkumab) for the treatment of adults with active psoriatic arthritis, making it the only IL-23 inhibitor with an indication for inhibiting the progression of structural damage.
Korean Translation
FDA, 활동성 건선성 관절염 성인 환자 치료를 위해 트렘피어®(구셀쿠맙)의 라벨 확장을 승인하여 구조적 손상 진행 억제 적응증을 가진 유일한 IL-23 억제제가 됨.
Related Recent Events
Target Corp (TGT) · Earnings Release
Target's Q2 2026 earnings release is set for August 19, 2026; low importance is estimated as the date announcement itself typically has a market impact of less than 5%, scheduled.
8/19/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Other
The U.S. FDA set a PDUFA target action date for iberdomide on 2026-08-17; importance is Low as the setting of a PDUFA date is a procedural event with minor price impact.
8/17/2026, 12:00:00 AM
AST SpaceMobile Inc (ASTS) · Earnings Release
Q2 2026 earnings release and conference call for August 10, 2026, which is expected to have a medium impact by providing key financial updates, scheduled.
8/10/2026, 12:00:00 AM
Chevron Corp (CVX) · Earnings Release
Q2 2026 earnings release is scheduled for August 7, 2026; analysts forecast a significant increase in earnings due to higher oil prices and full integration of Hess assets. Market impact is estimated at Medium (5%) as earnings are a primary driver of stock volatility, scheduled.
8/7/2026, 12:00:00 AM
Akamai Technologies Inc (AKAM) · Earnings Release
Q2 2026 earnings release scheduled for 2026-08-06. Analysts forecast EPS of around $1.60 forecasted. High importance estimated due to the 26% price movement in the previous earnings release scheduled.
8/6/2026, 12:00:00 AM
Consolidated Edison Inc. (ED) · Earnings Release
Q2 2026 earnings release on 2026-08-06 is scheduled. Low importance is estimated as the primary market impact occurs on the release date, scheduled.
8/6/2026, 12:00:00 AM